Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.

David VrabelLenka SedlarikovaLenka BesseLucie RihovaRenata BezdekovaMartina AlmasiVeronika KubaczkovaLucie BrožováJiri JarkovskyHana PlonkovaTomas JelinekViera SandeckaMartin StorkLudek PourSabina Sevcikova Roman Hájek

Published in: European journal of haematology (2019)

These results support the concept of tumor-specific cell-free DNA as a prognostic marker.

Keyphrases

end stage renal disease
multiple myeloma
ejection fraction
newly diagnosed
chronic kidney disease
mesenchymal stem cells
cell therapy